Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Change in Cash (2020 - 2025)

LifeStance Health (LFST) has disclosed Change in Cash for 6 consecutive years, with $44.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash fell 13.89% to $44.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $94.1 million, a 24.19% increase, with the full-year FY2025 number at $94.1 million, up 24.19% from a year prior.
  • Change in Cash was $44.7 million for Q4 2025 at LifeStance Health, up from $15.0 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $54.6 million in Q2 2025 to a low of -$64.1 million in Q4 2021.
  • A 5-year average of $3.2 million and a median of $13.1 million in 2023 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: tumbled 482.68% in 2023, then skyrocketed 231.69% in 2024.
  • LifeStance Health's Change in Cash stood at -$64.1 million in 2021, then soared by 128.53% to $18.3 million in 2022, then surged by 98.08% to $36.2 million in 2023, then soared by 43.45% to $52.0 million in 2024, then fell by 13.89% to $44.7 million in 2025.
  • Per Business Quant, the three most recent readings for LFST's Change in Cash are $44.7 million (Q4 2025), $15.0 million (Q3 2025), and $54.6 million (Q2 2025).